Pulmonary Pharmacology and Therapeutics Pulmonary Pharmacology and Therapeutics RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Editorial Board
Publication date: August 2019Source: Pulmonary Pharmacology & Therapeutics, Volume 57Author(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 17, 2019 Category: Respiratory Medicine Source Type: research

Publisher’s Note
Publication date: Available online 12 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 13, 2019 Category: Respiratory Medicine Source Type: research

First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis
ConclusionsSPX-101 was well-tolerated across a range of doses and had little/no systemic exposure in healthy adults and adults with CF, thus supporting further study in patients with CF.Clinicaltrial.gov registrationNCT03056989. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 12, 2019 Category: Respiratory Medicine Source Type: research

Effects of pidotimod and bifidobacteria mixture on clinical symptoms and urinary metabolomic profile of children with recurrent respiratory infections: A randomized placebo-controlled trial
ConclusionsPreschool children with RRI treated with pidotimod have better clinical outcomes and a different urine metabolomic profile than subjects receiving placebo. Further investigations are needed to clarify the connection between pidotimod and gut microbiome.Graphical abstract (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 12, 2019 Category: Respiratory Medicine Source Type: research

Utility of open surgical lung biopsy in children
ConclusionOLB contributed substantially in obtaining a definitive diagnosis for our patient population, no increase in mortality. It allowed targeted treatment and provided valuable prognostic information on the likely progression of the disease so families could plan for palliation where appropriate. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 4, 2019 Category: Respiratory Medicine Source Type: research

Hypoxia-inducible factor-2α and refractory nsclc: Further evidence to support the use of immune-checkpoint inhibitors?
Publication date: Available online 3 July 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Raffaella Mormile (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - July 4, 2019 Category: Respiratory Medicine Source Type: research

Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
ConclusionsSingle-dose ensifentrine demonstrated dose-dependent bronchodilation, and was as effective as a therapeutic dose of nebulised salbutamol. All ensifentrine doses were similarly well tolerated, and did not show the characteristic β2-agonist systemic adverse effects. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - June 14, 2019 Category: Respiratory Medicine Source Type: research

Pharmacokinetics of ambrisentan in a patient with Pulmonary Arterial Hypertension and a total gastrectomy
Publication date: Available online 12 June 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Eric Abston, Harrison W. FarberAbstractSignificant advances have been made in the treatment of arterial pulmonary hypertension (PAH). However, no studies to date have assessed the impact of altered gastrointestinal (GI) anatomy or absorption on the efficacy and bioavailability of oral medications in the treatment of PAH. Here, we describe the treatment of a patient with PAH initially treated with epoprostenol. Subsequently, an intractable upper GI bleed required a total gastrectomy. With epoprostenol, there was near norma...
Source: Pulmonary Pharmacology and Therapeutics - June 12, 2019 Category: Respiratory Medicine Source Type: research

Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes
Publication date: Available online 10 June 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Birk Poller, Ralph Woessner, Avantika Barve, Hanns-Christian Tillmann, Janardhana Vemula, Alexandra Nica, Walid Elbast, Hilmar Schiller, Peter End, Gian Camenisch, Markus WeissAbstractFevipiprant, a prostaglandin D2 receptor 2 antagonist, is in clinical development as a treatment for asthma. The goal of this study was to assess the potential of fevipiprant to cause drug-drug interactions (DDI) as a perpetrator, that is, by altering the pharmacokinetics (PK) of co-medications.In vitro drug interaction studies of clinically...
Source: Pulmonary Pharmacology and Therapeutics - June 11, 2019 Category: Respiratory Medicine Source Type: research

Characteristics of Chinese chronic cough patients
Publication date: Available online 6 June 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Li Long, Kefang LaiAbstractChronic cough is one of the most common complains for patients seeking medical attention in both general practice and respiratory specialist clinics. Cough variant asthma, eosinophilic bronchitis, upper airway cough syndrome, as well as gastro-esophageal reflux disease are common conditions associated with chronic cough, and cough variant asthma, eosinophilic bronchitis account for a higher proportion of patients with chronic cough in China than in Western countries. An older female predominance ...
Source: Pulmonary Pharmacology and Therapeutics - June 7, 2019 Category: Respiratory Medicine Source Type: research

Bronchiectasis and cough: An old relationship in need of renewed attention
Publication date: Available online 6 June 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): Micheál Mac Aogáin, Sanjay Haresh ChotirmallAbstractBronchiectasis is an increasingly recognised respiratory condition with limited therapeutic options and a complex spectrum of clinical manifestations that invariably includes chronic cough. As the primary presentation of bronchiectasis in most cases, chronic cough and its mechanistic underpinnings are of central importance but remain poorly understood in this setting. Bronchiectasis is also increasingly identified as an underlying cause of chronic cough highlighting the...
Source: Pulmonary Pharmacology and Therapeutics - June 7, 2019 Category: Respiratory Medicine Source Type: research

Nicotinic receptor dependent regulation of cough and other airway defensive reflexes
We present evidence that these nicotinic receptors are components of essential transducing and encoding mechanisms regulating airway defense. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - June 7, 2019 Category: Respiratory Medicine Source Type: research

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials
Publication date: Available online 30 May 2019Source: Pulmonary Pharmacology & TherapeuticsAuthor(s): James F. Donohue, Gregory Feldman, Sanjay Sethi, Chris N. Barnes, Srikanth Pendyala, David Bourdet, Glenn CraterAbstractThe cardiovascular safety of revefenacin, an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive lung disease (COPD), was evaluated in phase 3 trials in patients with moderate to very severe COPD. No clinically meaningful changes in 12-lead electrocardiogram recordings were observed with up to 52 weeks of once-daily revefenacin 88 or 175 μg. In a pooled analysis...
Source: Pulmonary Pharmacology and Therapeutics - May 31, 2019 Category: Respiratory Medicine Source Type: research

Interaction between blood lead level and chronic obstructive pulmonary disease (COPD) on risk of heart attack or stroke: USA NHANES, 2013–2014
ConclusionsThe low lead level today means more effect of COPD on the occurrence of heart attack and stroke. More studies required to understand the pathways of the association of COPD, CVD and lead due to their shared risk factors. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 19, 2019 Category: Respiratory Medicine Source Type: research

Intra-tracheal amikacin spray delivery in healthy mechanically ventilated piglets
ConclusionNebulization remains the most reliable and simple technique to deliver inhaled amikacin uniformly to the lung during mechanical ventilation. Further development of tracheal sprays is required to take advantage of potential benefits related to high drug output and low extra-pulmonary deposition in large animals. (Source: Pulmonary Pharmacology and Therapeutics)
Source: Pulmonary Pharmacology and Therapeutics - May 16, 2019 Category: Respiratory Medicine Source Type: research